Participants in the FORWARD-53 trial had clinically significant improvements in time-to-rise, among other metrics.
Wave’s DMD program, centered around WVE-N531, has shown promise as an alternative exon-skipping therapy. The company sees an opportunity in this space following Sarepta Therapeutics (NASDAQ ...
Wave’s DMD program, centered around WVE-N531, has shown promise as an alternative exon-skipping therapy. The company sees an opportunity in this space following Sarepta Therapeutics (NASDAQ:SRPT)’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback